公募基金方面，本期较上一季未再披露的公募基金共计2个，包括工银医疗保健股票、圆信永丰兴源 A。 2025年8月26日，拱东医疗(605369.SH)发布2025年半年度报告。截至2025年8月25日，共有4个机构投资 者披露持有拱东医疗A股股份，合计持股量达1902.32万股，占拱东医疗总股本的8.63%。其中，机构投 资者包括台州金驰投资管理合伙企业(有限合伙)、国泰佳泰股票专项型养老金产品-招商银行股份有限公 司、浙江拱东医疗器械股份有限公司-第一期员工持股计划、国泰基金管理有限公司-社保基金2103组 合，机构投资者合计持股比例达8.63%。相较于上一季度，机构持股比例合计下跌了0.59个百分点。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 对于社保基金，本期新披露持有拱东医疗的社保基金共计1个，即国泰基金管理有限公司-社保基金2103 组合。 ...

Policy Developments - The National Medical Products Administration (NMPA) has released multiple registration review guidelines for cancer screening in vitro diagnostic reagents, aiming to further standardize the management of these products [1] Medical Device Approvals - Sinno Medical announced that its subsidiary received a medical device registration certificate for a disposable microcatheter, which will enhance its product portfolio in the neurointerventional sector [2] - Heng Rui Medicine received approval for clinical trials of HRS-6093 tablets, a novel oral KRASG12D inhibitor, and HRS-2162 injection, a new generation muscle relaxant antagonist, both of which currently have no similar products approved in the market [3] - Mayinglong's subsidiary obtained a drug registration certificate for Olopatadine Hydrochloride eye drops, used for treating allergic conjunctivitis [4] Financial Reports - Xiaofang Pharmaceutical reported a 3.06% year-on-year increase in revenue to 270 million yuan and a 1.69% increase in net profit to 121 million yuan for the first half of the year [5] - Renhe Pharmaceutical's revenue decreased by 16.46% to 1.975 billion yuan, with a net profit decline of 13.87% to 290 million yuan for the same period [6] - China National Pharmaceutical Group announced a revenue of 286 billion yuan and an operating profit of 7.45 billion yuan for the first half of the year, with a gross margin of 7.11% [7] Capital Market Activities - BeiGene entered into a royalty purchase agreement with Royalty Pharma, agreeing to pay $885 million for the rights to a significant portion of royalties from the monoclonal antibody Imdelltra outside of China [9] - Terumo Corporation announced a $1.5 billion acquisition of OrganOx to expand its presence in the transplant medicine sector, focusing on liver preservation technology [10] Industry Developments - A domestic team has successfully utilized brain-computer interface technology for precise diagnosis and treatment of hydrocephalus, significantly reducing diagnosis time from 2-3 days to 30 minutes, marking a breakthrough in the application of this technology [11] - Sailun Biotech has launched its rabies serum product for sale in several provinces, becoming the only company to market this product [12] Corporate News - Yifeng Pharmacy announced the resignation of its Vice President, Zhang Jia, due to personal reasons [13]

根据市场公开信息及8月25日披露的机构调研信息，知名私募复胜资产近期对1家上市公司进行了调研， 相关名单如下： 1）乐普医疗 （上海复胜资产参与公司业绩说明会） 个股亮点：乐普瑞康(北京)养老服务管理有限公司为公司的子公司，公司持有其70.18%股权，主要从事 老人养老服务，护理服务。；公司自主研发的聚乳酸面部填充剂（俗称"童颜针"）已获得国家药品监督 管理局（NMPA）注册批准；公司的人工智能产品主要是搭载AI-ECG的各种生命指征监测类的硬件产 品，针对不同应用场景，外形包括但不限于各种可穿戴设备（戒指、手环、心贴）、pad类、台式机等 机构简介： 上海复胜资产管理合伙企业（有限合伙）成立于2015年，是国内首批以研究驱动为导向的阳光私募基金 管理公司。公司目前纯权益管理规模超过60亿。公司核心投研团队有16年以上大陆、香港、美国三地投 资经验，主要基金经理均有国内顶级公募投资经验。我们秉持"复利致胜"的原则，坚持业绩驱动投资， 重视投资的可持续性，致力为投资者获取长期的稳健收益。公司凭借优异的成绩，曾获中国证券报2019 年度第十一届三年期金牛私募投资经理（股票策略）、2020/2021年度第十一届金阳 ...

Group 1: Company Insights - XW Rich Fund recently conducted research on eight listed companies, including StarNet Ruijie, which focuses on optical communication and aims to enhance its AI capabilities [1] - Zhaoyi Innovation reported strong growth across its business lines, with NOR Flash experiencing high single-digit growth and niche DRAM growing over 50% [2] - Huijia Times optimized its product structure, achieving over 90% similarity with leading brands, and has seen increased sales and customer traffic since its store reopening [3] - Trina Solar emphasized the importance of fair competition in the photovoltaic industry and aims for over 8GWh in its energy storage segment, with a significant increase in overseas orders [4] - Baillie Tianheng is advancing multiple clinical trials for cancer treatments and aims to become a leading player in oncology within five years [5] - Cambridge Technology is expanding its production capacity for 800G series products and plans to finance future expansions through Hong Kong issuance [6] - Tianyu Co. reported improved gross margins across its business segments, with a focus on expanding its product offerings in endocrine and metabolic categories [7] - Lianying Laser achieved a revenue of 1.533 billion yuan in the first half of 2025, with a 5.3% year-on-year growth, and has set an annual order target of 4.5 billion yuan [8] Group 2: Industry Trends - The optical industry is focusing on technology advancements, with TOPCon technology becoming mainstream and layered battery technology being a key development direction [4] - The demand for customized storage technology is expected to grow, with more industries opting for tailored solutions due to performance advantages [2] - The pharmaceutical industry is seeing a rise in clinical trials for innovative cancer treatments, indicating a robust pipeline for future drug development [5] - The semiconductor market is experiencing tight supply for niche DRAM, leading to increased contract prices and overall revenue growth [2] - The retail sector is enhancing customer experience through store redesigns and product offerings, aiming to compete with leading brands [3]

Group 1: Company Insights - Jin Ying Fund recently conducted research on six listed companies, including Wenjian Medical, which reported a 13% year-on-year growth in Q2 and plans to enhance product structure and production efficiency [1] - Te Bao Bio is focusing on functional cure for hepatitis B, exploring combination therapies and expanding its clinical management network [1] - Rui Jie Network's data center product revenue growth is driven by internet clients, with over 90% of revenue coming from this sector, and expects continued strong demand for cloud computing infrastructure [2] - Bai Li Tian Heng is collaborating with BMS on key clinical trials for cancer treatments and has made progress in its nuclear medicine platform [3] - Lian Ying Laser achieved a revenue of 1.533 billion yuan in H1 2025, with a 5.3% year-on-year increase, and has set an annual order target of 4.5 billion yuan [4][5] - Lepu Medical's subsidiary focuses on elderly care services, and the company has received approval for its self-developed facial filler product [6] Group 2: Industry Trends - The medical sector is seeing significant growth potential, particularly in high-end dressings and health personal care, with a focus on optimizing product mix and channel structure [1] - The internet industry is expected to continue increasing capital expenditure on intelligent computing, indicating a robust demand for data center products [2] - The oncology treatment market is evolving with new drug candidates entering clinical trials, reflecting a growing focus on innovative cancer therapies [3] - The lithium battery equipment market is experiencing steady growth, with significant orders from both lithium and non-lithium sectors [4][5] - The healthcare technology sector is advancing with AI-integrated monitoring devices, indicating a trend towards more personalized and efficient healthcare solutions [6]

个股亮点：乐普瑞康(北京)养老服务管理有限公司为公司的子公司，公司持有其70.18%股权，主要从事 老人养老服务，护理服务。；公司自主研发的聚乳酸面部填充剂(俗称"童颜针")已获得国家药品监督管 理局(NMPA)注册批准；公司的人工智能产品主要是搭载AI-ECG的各种生命指征监测类的硬件产品，针 对不同应用场景，外形包括但不限于各种可穿戴设备(戒指、手环、心贴)、pad类、台式机等 红土创新基金成立于2014年，截至目前，资产管理规模(全部公募基金)180.45亿元，排名124/210；资产 管理规模(非货币公募基金)85.48亿元，排名127/210；管理公募基金数41只，排名111/210；旗下公募基 金经理13人，排名95/210。旗下最近一年表现最佳的公募基金产品为红土创新新兴产业混合，最新单位 净值为2.08，近一年增长129.76%。旗下最新募集公募基金产品为红土创新景气回报混合A，类型为混 合型-偏股，集中认购期2025年8月18日至2025年9月5日。 1)乐普医疗（300003）(红土创新基金参与公司业绩说明会) 证券之星消息，根据市场公开信息及8月25日披露的机构调研信息，红土创新基金近期 ...

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]

Core Viewpoint - The announcement from HeartTech Medical (02291) indicates that its major shareholder, Lepu Medical (300003), will sell 11.14 million H-shares at a price of HKD 22.79 per share, representing approximately 3.21% of the total issued shares, to enhance liquidity while maintaining a significant ownership stake of 77.54% in the company [1] Group 1 - HeartTech Medical's board has been informed by Lepu Medical about the sale of shares [1] - The sale involves 11.14 million H-shares at a price of HKD 22.79 each [1] - Post-sale, Lepu Medical will hold 268.86 million shares, which includes direct and subsidiary holdings [1] Group 2 - The sale is aimed at improving the liquidity of HeartTech Medical's stock [1] - Lepu Medical expresses strong confidence in the business operations of HeartTech Medical [1] - The ownership stake of Lepu Medical after the sale will be approximately 77.54% of the total issued shares [1]

智通财经APP讯，心泰医疗(02291)发布公告，本公司董事会已获本公司其中一名控股股东乐普(北京)医 疗器械股份有限公司(乐普医疗，其股份于深圳证券交易所创业板上市，证券代码：300003)告知，乐普 医疗于2025年8月26日通过大宗交易出售合共1114万股本公司H股，每股价格为22.79港元，占本公司于 本公告日期已发行股份总数的约3.21%(出售事项)。于出售事项后，乐普医疗将继续持有2.6886亿股股 份，包括由乐普医疗直接持有的2.6606亿股股份及由乐普医疗的附属公司北京天地和协科技有限公司持 有的280万股股份，占本公司于本公告日期已发行股本约77.54%，彰显其对本公司的坚定信心。乐普医 疗对本集团的业务运营充满信心，出售事项旨在提升本公司股票的流动性。 ...

宏观策略 [Table_MacroStrategy] 宏观点评 20250824：9 月降息的确定性与年内降息的变数 核心观点：本周美国经济数据好于预期，一度令 9 月降息预期回落，但 周五 Jackson Hole 央行会议 Powell 发表鸽派讲话，认为风险平衡要求调 整货币政策立场，为 9 月降息铺路。降息交易带动美股反弹、美元和美 债收益率大跌。乐观情形下，我们预计 9、12 月各降息一次，全年降息幅 度难超过 50bps，短期仍需关注 9 月密集数据对年内降息预期的扰动，当 前市场定价全年降息 2.2 次的降息预期偏乐观，面临回调风险。中期看， 我们预期 2026 年 5 月美联储新主席上台后，货币政策将更宽松，悲观、 基准、乐观情形下明年将分别有 4、5、6 次降息。9 月 FOMC 后，市场 当前计价的 2026 年仅 3 次的降息预期料将升温，届时 2 年美债利率、美 元指数将重新回归下行趋势。 宏观量化经济指数周报 20250824：货物吞吐量延续高位，8 月出口仍有 韧性 证券研究报告 东吴证券晨会纪要 东吴证券晨会纪要 2025-08-26 降准等总量宽松，仍有待外部风险、三季度经济增 ...